Division of Infectious Diseases, Children's Hospital Los Angeles, Los Angeles, California.
Keck School of Medicine, University of Southern California, Los Angeles, California.
Pediatrics. 2022 Feb 1;149(2). doi: 10.1542/peds.2021-054260.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies have been detected in human milk up to 6 weeks post-coronavirus disease 2019 (COVID-19) vaccination. We evaluated SARS-CoV-2-specific antibodies, neutralization activity, effect of pasteurization, and persistence through 6 months after vaccination.
This prospective longitudinal study enrolled 30 pregnant or lactating women. SARS-CoV-2 antibodies and neutralization capacity were analyzed using an enzyme-linked immunosorbent assay compared at prevaccination and 1, 3, and 6 months postvaccination, and through Holder pasteurization.
Human milk SARS-CoV-2-specific IgG levels peaked at 1 month postvaccination and persisted above prevaccination levels for at least 6 months (P = .005). SARS-CoV-2-specific IgA was detected at 1 and 3 months (both P < .001) but waned by 6 months compared with baseline (P = .07). Milk SARS-CoV-2-specific IgG and IgA correlated with serum IgG at the same time point (R2 = 0.37, P < .001 and R2 = 0.19, P < .001). Neutralization activity was seen in 83.3%, 70.4%, and 25.0% of milk samples at 1, 3, and 6 months postvaccination. Neutralization most strongly correlated with SARS-CoV-2-specific IgG (R2 = 0.57, P < .001). Pre- and postpasteurization samples showed similar IgG (0.84 vs 1.07, P = .36) and neutralizing activity (57.7% vs 58.7% inhibition, P = .27), but lower IgM and IgA levels postpasteurization (0.09 vs 0.06, P = .004 and 0.21 vs 0.18, P = .043).
The data suggest that human milk SARS-CoV-2-specific antibodies may be available to milk-fed infants for up to 6 months. In addition, donor milk from vaccinated mothers retain IgG and neutralizing activity.
在新型冠状病毒病 2019(COVID-19)疫苗接种后,人乳中已检测到针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的特异性抗体。我们评估了疫苗接种后 6 个月内 SARS-CoV-2 特异性抗体、中和活性、巴氏消毒的影响和持续存在。
这项前瞻性纵向研究纳入了 30 名孕妇或哺乳期妇女。使用酶联免疫吸附试验分析 SARS-CoV-2 抗体和中和能力,在接种前和接种后 1、3 和 6 个月进行比较,并通过Holder 巴氏消毒法进行比较。
人乳 SARS-CoV-2 特异性 IgG 水平在接种后 1 个月达到峰值,至少在 6 个月内持续高于接种前水平(P=0.005)。SARS-CoV-2 特异性 IgA 在 1 个月和 3 个月时均被检测到(均 P<.001),但与基线相比在 6 个月时减弱(P=0.07)。与同一时间点的血清 IgG 相比,乳汁 SARS-CoV-2 特异性 IgG 和 IgA 存在相关性(R2=0.37,P<.001 和 R2=0.19,P<.001)。在接种疫苗后 1、3 和 6 个月时,83.3%、70.4%和 25.0%的乳样中可检测到中和活性。中和活性与 SARS-CoV-2 特异性 IgG 相关性最强(R2=0.57,P<.001)。巴氏消毒前后的样本 IgG 水平相似(0.84 对 1.07,P=0.36)和中和活性相似(57.7%对 58.7%抑制,P=0.27),但巴氏消毒后 IgM 和 IgA 水平较低(0.09 对 0.06,P=0.004 和 0.21 对 0.18,P=0.043)。
数据表明,人乳中针对 SARS-CoV-2 的特异性抗体可提供给母乳喂养的婴儿长达 6 个月。此外,来自接种疫苗母亲的捐赠乳保留 IgG 和中和活性。